Relapsed or Refractory Large B-cell Lymphoma

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

ADC Therapeutics
ADC TherapeuticsNJ - New Providence
1 program
1
Loncastuximab TesirinePhase 21 trial
Active Trials
NCT06788964RecruitingEst. Mar 2030

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
2030
ADC TherapeuticsLoncastuximab Tesirine

Clinical Trials (1)

NCT06788964ADC TherapeuticsLoncastuximab Tesirine

Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)

Start: Aug 2025Est. completion: Mar 2030
Phase 2Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space